FDA GRAS Rule 2026: Key Changes, compliance & Industry Impact

FDA’s 2026 GRAS Proposal: Redefining Transparency in Food Ingredient Safety

By 2026, the U.S. Food and Drug Administration (FDA) is expected to introduce a proposed regulation requiring all Generally Recognized as Safe (GRAS) determinations to be formally notified to the agency. This pivotal development could effectively end the long-standing practice of self-affirmed GRAS and mark the beginning of a new era defined by transparency, accountability, and regulatory oversight.

Understanding GRAS and Its Importance

The GRAS framework has long served as a cornerstone of food ingredient regulation under the Federal Food, Drug, and Cosmetic Act. It allows substances to be used in food if qualified experts determine—based on publicly available scientific evidence—that they are safe under intended conditions of use.

Until now, companies have had two options:

• Submit a GRAS notification to the FDA for review

• Self-affirm GRAS status internally without notifying the agency

While both pathways have been legally valid, self-affirmation has faced criticism for creating a lack of transparency, with safety data often remaining undisclosed. The proposed 2026 GRAS Inventory Rule aims to close this gap by mandating notification and establishing a public inventory of all GRAS determinations.

Key Features of the Proposed Rule

Feature	Description
Mandatory transparency	All GRAS determinations must be submitted to the FDA
Public inventory	FDA will publish notifier details, intended use, and supporting safety evidence
Standardized dossiers	Submissions must comply with FDA GRAS notice format (21 CFR Part 170 Subpart E)
Global alignment potential	Enhanced transparency may support alignment with international regulatory expectations

Industry Impact: Preparing for Change

The proposed regulation is expected to significantly impact stakeholders across the food and beverage ecosystem:

• Ingredient developers: Will need stronger toxicological data, exposure assessments, and robust scientific validation

• Food & beverage brands: May face increased regulatory scrutiny and longer timelines for product approvals

• Regulatory affairs teams: Will require more structured, cross-functional approaches to dossier preparation

• Consumers: Will benefit from greater transparency and improved trust in food safety decisions

Transparency as a Driver of Innovation

Beyond compliance, the shift toward mandatory GRAS notification is likely to reshape innovation strategies:

• Innovation pressure: Preference for well-researched, scientifically defensible ingredients

• Open data ecosystem: Public GRAS inventory enables benchmarking and competitive insights

• Global harmonization: Transparent data may support acceptance across multiple regulatory markets

• Market differentiation: Brands embracing transparency can position themselves as leaders in safety and trust

Conclusion

The FDA’s proposed 2026 GRAS Inventory Rule represents a fundamental shift in how food ingredient safety is evaluated and communicated. The focus is moving from speed to market toward scientific rigor, transparency, and public accountability.

For organizations, success will depend on building strong, defensible safety dossiers that can withstand both regulatory and public scrutiny. In this evolving landscape, transparency is no longer optional—it is a strategic imperative.

At Freyr, we support companies through this transition with end-to-end regulatory expertise—from ingredient safety evaluation to compliant dossier preparation—ensuring innovation remains both credible and market-ready. Transparency is the new compliance currency, and Freyr helps turn it into a competitive advantage.